×

Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient

  • US 9,388,223 B2
  • Filed: 01/03/2013
  • Issued: 07/12/2016
  • Est. Priority Date: 01/05/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a myostatin-related disease, comprising administering to a subject having a myostatin-related disease, an extracellular water-soluble domain of a delta-like 1 homolog (DLK1) comprising the sequence of SEQ ID NO:

  • 34, a fragment of the extracellular water-soluble domain of DLK1, wherein the fragment comprises the sequence of SEQ ID NO;

    34, a mutant of the extracellular water-soluble domain of DLK1, wherein the mutant comprises the sequence of SEQ ID NO;

    34, or a fragment of the mutant, wherein the fragment comprises the sequence of SEQ ID NO;

    34, as an active ingredient.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×